P=0.046) The TAVR group had had more deaths and strokes between 1 and 2 years compared with the SAVR group, according to the PARTNER 3 investigators led by Martin Leon, MD, of Columbia University Irving Medical Center in New York City. Their report was published in the March 9 issue of the "Clearly, ongoing assessment of clinical and echocardiographic findings is needed in younger and low-risk patients and planned follow-up in PARTNER 3 will continue through at least 10 years," Leon and colleagues wrote. The convergence in death and stroke came as no surprise to cardiac surgeon Joseph Bavaria, MD, of the Hospital of the University of Pennsylvania in Philadelphia, who participated in the trial.